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Objectives. We sought to assess the relation between glucose
metabolism, myocardial perfusion and cardiac work after ortho-
topic heart transplantation.
Background. The metabolic profile of the transplanted cardiac
muscle is affected by the lack of sympathetic innervation, impaired
inotropic function, chronic vasculopathy, allograft rejection and
immunosuppressive therapy. In relation to myocardial perfusion
and cardiac work, glucose metabolism has not previously been
studied in heart transplant recipients.
Methods. Regional myocardial blood flow (mlzmin21zg21) and
18F-2-fluoro-2-deoxyglucose (18FDG) uptake rate (mlzs21zg21)
were measured after an overnight fast in 9 healthy male volun-
teers (mean age 6 SD 32 6 7 years) and in 10 male patients
(mean age 50 6 10 years) who had a nonrejecting heart trans-
plant, normal left ventricular function and no angiographic evidence
of epicardial coronary sclerosis. Measurements were made by using
dynamic positron emission tomography (PET) with 15O-labeled
water and 18FDG, respectively. Heart rate and blood pressure
were also measured for calculation of rate-pressure product.
Results. 18FDG uptake was similar in all heart regions in the
patients and volunteers (intrasubject regional variabily 12 6 8%
and 16 6 12%, respectively, p 5 0.51). Regional myocardial blood
flow was similarly evenly distributed (intrasubject regional vari-
ability 14 6 10% and 12 6 8%, respectively, p 5 0.67). Mean
18FDG uptake and myocardial blood flow values for the whole
heart are given because no regional differences were identified.
18FDG uptake was on average 196% higher in the patients than in
the volunteers (2.90 6 1.79 3 1024 vs. 0.98 6 0.38 3 1024
mlzs21zg21, p 5 0.006). Regional myocardial blood flow and
rate-pressure product were similarly increased in the patient
group, but by only 41% (1.14 6 0.3 vs. 0.81 6 0.13 mlzmin21zg21,
p 5 0.008) and 53% (11,740 6 2,830 vs. 7,689 6 1,488, p 5 0.001),
respectively.
Conclusions. 18FDG uptake is homogeneously increased in
normally functioning nonrejecting heart transplants. This finding
suggests that glucose may be a preferred substrate in the trans-
planted heart. The magnitude of this observed increase is signif-
icantly greater than that observed for myocardial blood flow or
cardiac work. In the patient group, the latter two variables were
increased to a similar degree over values in control hearts,
indicating a coupling between cardiac work load and myocardial
blood flow. The disproportionate rise in 18FDG uptake may be
accounted for by inefficient metabolic utilization of glucose by the
transplanted myocardium or by the influence of circulating cat-
echolamines, which may stimulate glucose uptake independently
of changes in cardiac work load.
(J Am Coll Cardiol 1997;30:533–8)
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Under physiologic conditions the heart is an aerobic organ
with free fatty acid representing the major metabolic substrate
(1–3). After heart transplantation, although rest cardiorespi-
ratory function is normal, peak exercise performance has been
reported to be limited, probably owing to reduced maximal
cardiac performance (4–8). Factors that may account for this
finding include 1) lack of extrinsic sympathetic innervation
(9,10); 2) myocardial metabolic inefficiency due to chronic
denervation (10) or prolonged hypothermic storage of the
allografts (11–13); and 3) impaired inotropic function due to
altered sarcoplasmatic reticular handling of calcium (14).
Many of these data have been derived from experimental
animal studies where additional factors may affect cardiac
function; few results are available in humans.
Positron emission tomography (PET) is a radionuclide
imaging technique that allows quantitative assessment of var-
ious aspects of myocardial tissue function (15). Initial clinical
efforts have focused on quantifying myocardial blood flow and
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perfusion reserve of the transplanted heart (16,17). Drake-
Holland et al. (18) showed that glucose oxidation was signifi-
cantly reduced in comparison with other substrates in auto-
transplanted baboon hearts, attributing these observations to
disruption of the extrinsic autonomic innervation of the heart.
In human cardiac allograft recipients, factors in addition to
chronic denervation may influence myocardial glucose metab-
olism. These include 1) increased cardiac work load due to the
combination of increased heart rate (owing to loss of vagal
tone) and increased circulating catecholamine levels (8,16,17,19),
and cyclosporine-induced hypertension (20); 2) accelerated
coronary vasculopathy (21); and 3) allograft rejection (22).
Thus, in this study, we assessed myocardial glucose uptake
in vivo in 10 fasting patients with a nonrejecting cardiac
allograft and in 9 healthy human volunteers. Our studies used
PET scanning and the glucose analog 18F-2-fluoro-2-
deoxyglucose (18FDG) on the assumption that this variable
gives direct evidence of the glucose metabolic state in human
cardiac allografts.
Methods
Study group. Ten male nondiabetic orthotopic heart trans-
plant recipients, ranging in age from 29 to 62 years (mean 6
SD 50 6 10) were selected for this study. Before transplanta-
tion, eight patients had had end-stage heart failure due to
ischemic heart disease and two had had idiopathic dilated
cardiomyopathy. Tomographic studies were carried out 13 to
60 months (34 6 14 months) after transplantation. All patients
had neither a history nor physical findings consistent with heart
failure and had normal cardiac function on ventriculography
(left ventricular ejection fraction ranged from 57% to 78%
[mean 69 6 7%]), normal coronary angiographic findings and
no histologic or clinical findings of graft rejection. The mean
interval between the most recent annual cardiac evaluation
(angiography and endomyocardial biopsy) and the PET study
was 6 6 4 weeks. All patients were maintained on a regular
immunosuppressive regimen of cyclosporine, whose dose was
adjusted to maintain a blood level of 150 to 250 ngzml21, and
azathioprine (2 mgzkg21 body weight). No patient was taking
corticosteroids or beta-adrenoceptor agonists or antagonists.
Eight patients were receiving aspirin or dipyridamole, or both;
four patients were taking antihypertensive medication (nifed-
ipine in three; furosemide in one). No patient had clinical or
electrocardiographic (ECG) findings compatible with post-
transplantation myocardial infarction.
Nine male volunteers with an average age of 32 6 7 years
were recruited to construct a normal 18FDG uptake and
myocardial blood flow data base. None had previous symp-
toms, signs or ECG evidence of heart disease. None was taking
any medications.
Informed written consent was obtained from each patient.
The study protocol was approved by the Hammersmith and
Harefield Hospital Research Ethics Committees and the Ad-
ministration of Radioactive Substances Advisory Committee
(UK).
Scanning procedures. All subjects were studied after an
overnight fast. Apart from the immunosuppressive agents, all
medication was withheld 48 h before the tomographic study in
the transplant group. Imaging was performed with a multislice
ECAT 931/08-12 tomograph (CTI Inc.). Further details on the
physical performance of this scanner have been reported
elsewhere (23).
Each subject was first positioned within the scanner for a
5-min rectilinear transmission scan to allow optimal position-
ing of the heart in the center of the field of view of the camera.
A 20-min transmission scan was then performed by the expo-
sure of an external 68Ge ring source. These data were used to
correct subsequent emission scans for tissue attenuation of the
511-keV gamma photons. This scan was followed by an oxygen-
15–labeled carbon monoxide blood volume scan, as previously
described (24). When activity had decayed to background
levels, myocardial blood flow was measured by using oxygen-
15–labeled water (H2
15O) delivered by the inhalation of oxygen-
15–labeled carbon dioxide (C15O2). Scanning procedures and
myocardial blood flow data analysis have been reported previ-
ously in detail (24). After a 15-min interval to allow for decay
of oxygen-15 radioactivity, 18FDG (185 MBq) was infused
intravenously over 2 min. A 36-frame dynamic scan was started
30 s before the start of 18FDG infusion, thus enabling mea-
surement of residual background activity. This scan lasted for
65 min. In all subjects, venous blood samples for plasma
glucose were obtained before the scan to ensure fasting
conditions. The rate-pressure product (heart rate times systolic
blood pressure) was obtained during the image acquisition.
Data analysis. The emission data collected by the scanner
were corrected for tissue attenuation and reconstructed into
images with an inplane spatial resolution of 8.4 mm full width
at half maximum (FWHM) and a slice thickness of 6.6 mm
FWHM. These images were transferred to SUN 3/60 worksta-
tions (Sun Microsystems) for further image processing using
the Analyze (Mayo Foundation) software package (25) and
kinetic analysis using the MatLab mathematical software pack-
age (The MathWorks Inc.).
Definition of regions of interest. Vascular regions of inter-
est were defined on the quantitative images of blood volume,
as previously described (24,26). A mean of four left atrial
regions with an average size of 100 pixels (;4 cm2) and
recovery coefficients .90% were selected. These were then
Abbreviations and Acronyms
ANOVA 5 analysis of variance
C15O2 5 oxygen-15–labeled carbon dioxide
Dev 5 extravascular tissue density images
ECG 5 electrocardiographic
18FDG 5 18F-2-fluoro-2-deoxyglucose
FWHM 5 full width at half maximum
H2
15O 5 oxygen-15–labeled water
PET 5 positron emission tomography (tomographic)
tf 5 tissue fraction
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projected onto the dynamic H2
15O and 18FDG frames, thereby
creating left atrial time-activity curves for each tracer. The
average of these curves was used as arterial input function for
the calculation of myocardial blood flow and 18FDG uptake.
Tissue regions of interest of 5-pixel radius (equivalent to a
10-mm radius) were positioned in the four anatomic segments
of the myocardium (anterior, lateral, inferior and septum).
These were identified on each slice of the extravascular tissue
density images (Dev; g total [anatomic] tissue per ml region of
interest), created by subtracting images of blood density from
the corresponding transmission images after normalization of
the latter to tissue density (27). Tissue regions of interest were
then projected onto the dynamic H2
15O data set and onto the
last 10-min 18FDG data acquisition frame, recorded during the
period 55 to 65 min after the start of tracer administration, to
generate tissue time-activity curves for the four myocardial
segments. For each segment, the average regional H2
15O
time-activity curve was used to estimate myocardial blood flow.
Consistency of the vascular and tissue regions of interest was
checked on the H2
15O images and the 18FDG images to ensure
no significant patient movement during the scanning proce-
dures.
Calculation of regional myocardial blood flow and 18FDG
uptake. The vascular and tissue time-activity curves obtained
from the C15O2 inhalation blood flow study were fitted to a
single-tissue compartment tracer kinetic model as previously
described (24,26). This model incorporates correction for, 1)
the underestimation of tissue activity due to cardiac wall
motion and the small transmural myocardial thickness relative
to the spatial resolution of the scanner, and 2) the fractional
spillover of activity from the left ventricle into the tissue
regions of interest.
With use of the average of the left atrial 18FDG time-
activity curves, the area under the curve of the arterial input
function was calculated. The tissue regions of interest were
projected onto the last frame of the dynamic 18FDG data set.
This procedure allows determination of the accumulation of
18FDG in the different regions of the left ventricle. Regional
18FDG uptake (rFDGU; mlzs21zml ROI) was defined as the
ratio between the average 18FDG pixel counts in the tissue
regions of interest to the integral of the arterial input function:
rFDGU 5 Ctiss~T!YSE
0
T
Ca~t! dtD,
where Ctiss(T) represents the mean FDG activity (counts
zs21zpixel21) in the tissue regions of interest during the last frame
of the 18FDG scan and Ca(t) (countszs
21zpixel21) represents the
left atrial input function (28–30). Regional 18FDG uptake values
were corrected for partial volume effects by normalizing to tissue
fraction (tf, ml exchangeable tissue per ml region of interest) (27)
and converted from units of mlzs21zml21 to mlzs21zg21 by further
dividing by the density of myocardial tissue (1.04 gzml21).
Statistical methods. Data are expressed as mean value 6
SD. Statistical analysis was performed by using the Student’s t
test; multiple data sets were compared by analysis of variance
(ANOVA). If significant differences were found, post hoc
pairwise intergroup comparisons were performed by the ad-
justed t test within ANOVA (least significant difference test).
Correlation of coefficients was calculated with the least-
squares linear regression analysis. A p value , 0.05 was
considered significant.
Results
Clinical and tomographic data are summarized in Table 1.
Heart rate, systolic arterial pressure, rate-pressure product,
regional myocardial blood flow and regional 18FDG uptake
data were compared between the two groups. Rest heart rate,
systolic blood pressure and rate-pressure product were 25%,
24% and 53%, respectively, higher in the patients than in the
normal subjects (p 5 0.006, 0.001 and 0.001, respectively).
Regional myocardial blood flow. In both groups, myocar-
dial blood flow was homogeneously distributed in the four left
ventricular regions (anterior, lateral, inferior and septum).
Mean intrasubject regional variability was 14 6 10% in the
transplant patients and 12 6 8% in the normal volunteers (p 5
0.67). Mean regional myocardial blood flow was 41% higher in
the patients than in the volunteers (1.14 6 0.3 vs. 0.81 6
0.13 mlzmin21zg21, p 5 0.008). Mean values of perfusable
Table 1. Clinical and Tomographic Data of Heart Transplant
Recipients and Normal Volunteers
Subject No. Age (yr) HR BP RPP rMBF rFDGU
Transplant group
1 59 70 170 11,900 0.80 1.00
2 51 78 150 1,170 1.73 2.46
3 47 80 130 10,400 0.98 6.81
4 60 108 170 18,360 1.52 3.22
5 51 80 160 13,120 0.89 3.53
6 29 88 150 13,200 1.27 0.85
7 60 84 130 10,920 1.30 3.69
8 62 75 140 10,500 0.93 0.90
9 39 66 120 7,920 0.95 3.53
10 50 75 125 9,375 1.02 2.97
Mean 51 81 145 11,740 1.14 2.90
SD 10 12 18 2,830 0.3 1.79
Volunteer group
1 31 64 90 5,760 0.91 0.88
2 21 70 115 8,050 0.69 0.58
3 36 50 120 6,000 0.95 0.91
4 36 65 130 8,450 0.99 0.87
5 31 55 120 6,600 0.57 0.82
6 36 64 120 7,680 0.76 1.68
7 31 66 110 7,260 0.81 1.57
8 22 80 130 10,400 0.83 0.71
9 41 75 120 9,000 0.79 0.79
Mean 32 65 117 7,689 0.81 0.98
SD 7 9 12 1,488 0.13 0.38
p value* 0.006 0.001 0.001 0.008 0.006
*Transplant group versus volunteer group. BP 5 blood pressure (mm Hg);
HR 5 heart rate (beats/min); rFDGU 5 regional 18F-2-fluoro-2-deoxyglucose
uptake (3 1024 mlzs21zg21); rMBF 5 regional myocardial blood flow
(mlzmin21zg21); RPP 5 rate-pressure product (beats/min 3 mm Hg).
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tissue index (PTI 5 tf/Dev; g perfusable tissue per g total
(anatomic) tissue [27]) of regions of interest were comparable
between the two groups (1.05 6 0.04 vs. 1.03 6 0.03, p 5 0.87).
Mean rest cardiac work load as reflected by the rate-pressure
product was 53% higher in the patients than in the volunteers
(p 5 0.001).
18FDG regional uptake. In all transplant recipients and
normal volunteers, plasma glucose levels after an overnight
fast were ,100 mg/dl. In both groups, 18FDG uptake was
uniform (Fig. 1) in the four myocardial segments (p 5 0.89 for
both groups). In the patients, the mean intrasubject regional
variability of 12 6 8% was similar to that in the volunteers
(16 6 12%, p 5 0.51). Mean regional glucose uptake was 196%
higher in the patients than in the volunteers (2.90 6 1.79 3
1024 vs. 0.98 6 0.38 3 1024 mlzs21zg21, p 5 0.006). For the
combined group of patients and volunteers, and within each
group, no significant correlations were obtained between rate-
pressure product or regional myocardial blood flow or 18FDG
uptake. For the entire group of transplant recipients, there was
no significant correlation between 18FDG uptake and age, time
elapsed from transplantation or operative time of cold isch-
emia.
Discussion
In this study, regional myocardial perfusion and exogenous
glucose uptake were assessed with H2
15O and 18FDG, respec-
tively. Regional glucose uptake was found to be significantly
higher in patients with a nonrejecting heart transplant than in
healthy human volunteers, suggesting higher glucose utiliza-
tion in the patient group. However, the increment in glucose
uptake was disproportionately greater than the increments in
cardiac work load and regional myocardial blood flow.
Myocardial metabolism, perfusion autoregulation and
receptor-mediated cardiac responses of the orthotopic heart
transplant have gained increasing attention in the last few
years (10,16,17,19). Metabolic and perfusion alterations in the
transplanted human heart have been related to several factors:
the higher metabolic need of the transplanted heart compared
with that of the normal heart; the effects of chronic denerva-
tion and heart responsiveness to neurotransmitter compounds;
hormonal and circulating catecholamine changes after trans-
plantation; coronary vasculopathy; and chronic rejection and
immunosuppressive therapy. It has been suggested that pa-
tients with a transplanted heart are likely to function in a state
of myocardial metabolic inefficiency. These factors will be
discussed in greater detail later.
Pathogenesis and significance of 18FDG findings. The ho-
mogeneous increase in regional glucose uptake observed in
transplant recipients reflects an increased transmembrane
transport and phosphorylation of exogenous glucose, as the
phosphorylated compound 18FDG-6-phosphate cannot be me-
tabolized further. It is trapped within the cell in proportion to
the uptake and phosphorylation of exogenous glucose because
of its hydrophilic structure and its extremely slow myocardial
clearance (31,32). Therefore, these data give no indication as
to the ultimate metabolic fate of glucose in the transplanted
heart. Several hypotheses may explain the observation of
enhanced glucose uptake in transplants.
Metabolic demand. Increased cardiac work load may ex-
plain the increment in glucose uptake in the transplanted
heart. Studies in the isolated rat heart (33) have shown that
substrate utilization, in particular glucose, is related to the
degree of myocardial loading. Furthermore, such high work
load conditions may result in myocardial hypertrophy, which
may also explain a relatively enhanced glucose uptake in the
transplanted human heart. This has been demonstrated in
habitually pressure-overloaded normal hearts and is associated
with decreased free fatty acid analog extraction (33–36).
Hypercontractility may also lead to an increase in carbohydrate
utilization, as shown in patients with coronary artery disease
(37,38) and in isolated pig hearts (39). Therefore, in the
transplanted, normally functioning heart, enhanced glucose
uptake may be secondary to the high work load conditions
under which the heart operates.
Adrenergic mechanisms. Both alpha- and beta-adrenergic
mechanisms appear to be involved in the control of glucose
uptake by way of increasing cardiac contractility (40,41) and
activation of phosphofructokinase, the rate-limiting enzyme of
cardiac muscle glycolysis (42). Both adrenergic control of
glucose uptake and phosphofructokinase activity are calcium
dependent and influenced by alpha- and beta-adrenergic re-
ceptor mechanisms. Glucose uptake may be influenced not
only by alterations of circulating catecholamines, but also by
late cardiac sympathetic reinnervation and local release of
catecholamines from sympathetic neurons (8,43,44), ultimately
leading to a disproportionate rise in glucose uptake. In addi-
tion, as denervation is known to alter tissue adrenoceptor
density, it may be speculated that “up-regulation” of beta-
Figure 1. Bar graphs showing regional differences in myocardial
18F-2-fluoro-2-deoxyglucose (FDG) uptake (3 1024 mlzs21zg21) in
heart transplant recipients (Tx) and normal volunteers (Nl).
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adrenergic receptor density and a hypersensitivity to beta-
adrenergic receptor stimulation, as shown in in vitro studies
(45), may contribute to enhanced glucose uptake in the
transplanted heart. However, in myocardial tissue specimens
obtained from clinically stable heart transplant recipients,
neither beta-adrenergic receptor density nor the response of
adenylate cyclase to isoproterenol differed from that in normal
myocardium (46). A more recent study (47) has shown that
beta2 receptors are increased in transplanted human ventricles
whereas the total beta-adrenergic receptor density is un-
changed, resulting in a lower beta1 to beta2 receptor density
ratio (47). Thus, although upregulation of beta receptors
mediating the increase in glucose uptake is a teleologically
attractive hypothesis, supporting evidence is at present equivocal.
Coronary vasculopathy. Another possible explanation is
that myocardial blood flow to the human transplanted myocar-
dium is not proportionally increased to meet the higher
metabolic need of the transplanted heart. It is conceivable that
the myocardium suffers from a chronically inadequate coupling
of blood supply and metabolite requirement, resulting in a
pure “demand ischemia.” Thus the myocardium may be un-
derperfused, not in terms of absolute blood flow but in relation
to its higher metabolic requirement. This imbalance may be
enough to create a consistent metabolic shift of the whole
heart toward an increased glucose utilization, which then
becomes the main fuel source for the transplanted heart. In
contrast to the ischemic heart, where compromised perfusion
has long been equated with an increased glucose uptake in the
distribution territory of the ischemia-related vessel (28,38), the
inadequate perfusion-autoregulation coupling in the individual
transplanted heart appears not to be sufficiently critical to be
detectable with conventional perfusion agents unless a concur-
rent, rapidly developing coronary vasculopathy is superim-
posed. However, it may be sufficient to act as a potent substrate
modifier, causing enhanced glucose uptake. In this respect, it is
noteworthy that the presence of metabolic ischemia may occur
without detectable perfusion abnormalities under conditions
of increased cardiac work load (48,49).
In this group of cardiac allograft recipients, neither wall
motion abnormalities nor significant epicardial coronary le-
sions were demonstrable. Myocardial blood flow was homoge-
neously distributed and in the range reported for healthy
volunteers (50). Thus, myocardial ischemia, including silent
ischemia, is unlikely to account for the raised uniform regional
18FDG uptake observed in the heart transplants.
Metabolic aspects. Uptake and use of a given substrate by
the myocardium depends on a variety of factors, including
substrate availability, hormonal status, cardiac work load and
the presence and severity of myocardial ischemia. In the fasting
state, when plasma glucose levels are reduced and insulin
levels are low, the normal myocardium utilizes relatively little
glucose. The transplanted heart, operating at a higher demand
level, may consume relatively more glucose as a result of 1) a
reduced or insufficient availability of free fatty acids or,
alternatively, 2) a saturation or ineffectiveness of the beta-
oxidative pathway; 3) altered hormonal activity; 4) chronic
rejection; or 5) immunosuppressive therapy. In this context, it
has been demonstrated (34) that a decline in free fatty acid
concentration and an increase in glucose and insulin levels
result in a high uptake of 18FDG in normal myocardium and in
moderately injured, ischemic myocardium. Little is known
about the progression of metabolic derangement that may
reflect the duration of cyclosporine therapy and the metabolic
aspects of acute or chronic allograft rejection. Glucose may be
a preferred metabolic substrate during acute rejection, as
shown by Hoff et al. (22) in a nonworking experimental model.
In our group of transplant recipients, it is more likely that the
disproportionately high 18FDG uptake in relation to cardiac
work load and myocardial perfusion may represent decreased
metabolic efficiency of the transplanted myocardium (10); that
is, a greater amount of substrate needs to be utilized to generate
a given level of contractile performance, and or, a chronic
adaptation of myocardial metabolism to a situation of persistent
high work load conditions in the presence of raised circulating
catecholamine levels and or myocardial norepinephrine release,
resulting in altered patterns of substrate utilization.
Conclusions. The present study shows an increase in
18FDG uptake in nonrejecting orthotopic transplanted hearts,
which suggests increased glucose metabolism in these patients.
These findings suggest that glucose may be a preferred sub-
strate in heart transplants. Furthermore, as the increment in
18FDG uptake is disproportionately high compared with the
increments in cardiac work load and myocardial perfusion, this
functional-metabolic uncoupling may indicate a decreased
efficiency of glucose utilization or a stimulation of glucose
uptake by raised circulating catecholamine levels, which stim-
ulate glucose uptake in the chronically denervated trans-
planted heart independently of cardiac work load. Further
studies of substrate utilization under tightly fixed metabolic
conditions, such as the euglycemic hyperinsulinemic clamp
(51), and the relation between myocardial metabolism and
contractile function in heart transplants are warranted.
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